Literature DB >> 9301450

Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology.

D von Schweinitz1, D J Byrd, H Hecker, P Weinel, U Bode, D Bürger, R Erttmann, D Harms, H Mildenberger.   

Abstract

The Cooperative German Paediatric Liver Tumour Study HB89 was conceived to evaluate the efficiency and toxicity of ifosfamide, cisplatin and doxorubicin (IPA) in children with resectable and non-resectable hepatoblastoma (HB) and to determine late sequelae including tubular nephropathy of tumour treatment. The study also assessed the results of a surgical strategy, which adapts the procedure at the initial operation to the tumour's extension in the liver. The relationship of the tumours' histological differentiation to response to chemotherapy was also examined. Patients with a HB restricted to one liver lobe underwent primary resection. Larger tumours were initially treated with IPA chemotherapy and resected at second-look surgery. All patients received IPA adjuvantly after tumour resection. The IPA regimen consisted of ifosfamide 3.5 g/m2 (over 72 h days 1-3), cisplatin 100 mg/m2 (over 5 days 4-8) and doxorubicin 60 mg/m2 (over 48 h, days 9-10). Median follow-up of survivors was 64 months (range 28-82). Long-term disease-free survival (DFS) was for stage I: 21/21; stage II: 3/6; stage III: 28/38; and stage IV: 2/7 (overall 75%). Severe surgical complications occurred in 15% (4/27) of primary and 21% (8/38) of secondary resections with no lethality. 44/45 stage III/IV HB displayed PR after two IPA courses. Drug resistance developed in 8/12 tumours after four or five chemotherapy courses. Acute toxicity was observed in 34/242 (14%) IPA courses. Late sequelae were found in 7/54 (13%) of survivors, and subclinical renal tubulopathy occurred in 7/41 investigated patients (17%). Despite a more favourable prognosis in pure fetal and predominantly fetal histology, statistical analysis revealed no relationship between tumour differentiation and response to chemotherapy. In conclusion, IPA chemotherapy in combination with delayed surgery was highly effective in the treatment of HB.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301450     DOI: 10.1016/s0959-8049(97)00095-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  22 in total

1.  Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.

Authors:  R G Weber; T Pietsch; D von Schweinitz; P Lichter
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Treatment outcomes for hepatoblastoma: an institution's experience over two decades.

Authors:  J P Ang; J A Heath; S Donath; S Khurana; A Auldist
Journal:  Pediatr Surg Int       Date:  2006-11-21       Impact factor: 1.827

3.  Optimizing vector application for gene transfer into human hepatoblastoma cells.

Authors:  Steven W Warmann; Sorin Armeanu; Heike Heitmann; Peter Ruck; Guido Seitz; Johannes T Wessels; Marie-Luise Lemken; Ulrich M Lauer; Jörg Fuchs; Michael Bitzer
Journal:  Pediatr Surg Int       Date:  2006-07-29       Impact factor: 1.827

4.  Diagnostic and prognostic values of serum exosomal microRNA-21 in children with hepatoblastoma: a Chinese population-based study.

Authors:  Wanbo Liu; Sheng Chen; Bing Liu
Journal:  Pediatr Surg Int       Date:  2016-09-06       Impact factor: 1.827

5.  Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group.

Authors:  Marcio H Malogolowkin; Howard M Katzenstein; Rebecka L Meyers; Mark D Krailo; Jon M Rowland; Joel Haas; Milton J Finegold
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

Review 6.  Efficacy of neoadjuvant therapy and surgical rescue for locally advanced hepatoblastomas: 10 year single-center experience and literature review.

Authors:  Dolores Ayllon Teran; Oscar Gómez Beltran; Rubén Ciria Bru; Elena Mateos González; María José Peña Rosa; Antonio Luque Molina; Pedro López Cillero; Javier Briceño Delgado
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  ER stress and ASK1-JNK activation contribute to oridonin-induced apoptosis and growth inhibition in cultured human hepatoblastoma HuH-6 cells.

Authors:  Duo-te Cai; Hua Jin; Qi-Xing Xiong; Wei-Guang Liu; Zhi-gang Gao; Gui-xiong Gu; Yu-hui Qiu
Journal:  Mol Cell Biochem       Date:  2013-04-12       Impact factor: 3.396

8.  A trend of improved survival of childhood hepatoblastoma treated with cisplatin and doxorubicin in Taiwanese children.

Authors:  Shuenn-Nan Chiu; Yen-Hsuan Ni; Meng-Yao Lu; Dong-Tsamn Lin; Kai-Hsin Lin; Hong-Shiee Lai; Mei-Hwei Chang
Journal:  Pediatr Surg Int       Date:  2003-10-11       Impact factor: 1.827

9.  Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma.

Authors:  Regina V Oliveira; Joelle M Onorato; Danuta Siluk; Christine M Walko; Celeste Lindley; Irving W Wainer
Journal:  J Pharm Biomed Anal       Date:  2007-08-02       Impact factor: 3.935

Review 10.  Rare Tumors in Children: Progress Through Collaboration.

Authors:  Alberto S Pappo; Wayne L Furman; Kris A Schultz; Andrea Ferrari; Lee Helman; Mark D Krailo
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.